|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4714681A
(en)
|
1981-07-01 |
1987-12-22 |
The Board Of Reagents, The University Of Texas System Cancer Center |
Quadroma cells and trioma cells and methods for the production of same
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4925648A
(en)
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
EP0479909B1
(en)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
|
ES2284161T3
(es)
|
1990-01-12 |
2007-11-01 |
Amgen Fremont Inc. |
Generacion de anticuerpos xenogenicos.
|
|
JP3583420B2
(ja)
|
1990-10-05 |
2004-11-04 |
メダレツクス・インコーポレーテツド |
二特異的試薬を用いた標的免疫化
|
|
AU8727291A
(en)
|
1990-10-29 |
1992-06-11 |
Cetus Oncology Corporation |
Bispecific antibodies, method of production, and uses thereof
|
|
IE921342A1
(en)
|
1991-04-26 |
1992-11-04 |
Surface Active Ltd |
Novel antibodies, and methods for their use
|
|
WO1993017715A1
(en)
|
1992-03-05 |
1993-09-16 |
Board Of Regents, The University Of Texas System |
Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
|
|
US6111166A
(en)
|
1994-09-19 |
2000-08-29 |
Medarex, Incorporated |
Transgenic mice expressing human Fcα and β receptors
|
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
ES2544527T3
(es)
|
2002-07-31 |
2015-09-01 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
|
GB0226583D0
(en)
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
|
RU2350611C1
(ru)
|
2002-12-24 |
2009-03-27 |
Астразенека Аб |
Производные фосфонооксихиназолина и их фармацевтическое применение
|
|
MXPA05008688A
(es)
|
2003-02-17 |
2005-10-05 |
Pharmacia Italia Spa |
Derivados tetraciclicos de pirazol como inhibidores de la cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
|
|
GB0315657D0
(en)
|
2003-07-03 |
2003-08-13 |
Astex Technology Ltd |
Pharmaceutical compounds
|
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
US7141568B2
(en)
|
2003-07-09 |
2006-11-28 |
Pfizer Italia S.R.L. |
Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
EP1663242B1
(en)
|
2003-08-07 |
2011-04-27 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
|
|
ATE381566T1
(de)
|
2004-05-14 |
2008-01-15 |
Millennium Pharm Inc |
Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
|
|
US7754714B2
(en)
|
2004-05-18 |
2010-07-13 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
|
EP1781653A1
(en)
|
2004-07-05 |
2007-05-09 |
Astex Therapeutics Limited |
3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
|
|
MX2007000631A
(es)
|
2004-07-16 |
2007-03-30 |
Sunesis Pharmaceuticals Inc |
Tienopirimidinas utiles como inhibidores de aurora cinasa.
|
|
CN101056655A
(zh)
*
|
2004-10-01 |
2007-10-17 |
米德列斯公司 |
治疗cd30阳性淋巴瘤的方法
|
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
|
ATE421996T1
(de)
|
2004-11-15 |
2009-02-15 |
Rigel Pharmaceuticals Inc |
Verfahren zur herstellung optisch aktiver n- carbamat-geschützter beta-lactame durch optische auflösung unter verwendung einer candida antarctica lipase
|
|
WO2006070198A1
(en)
|
2004-12-30 |
2006-07-06 |
Astex Therapeutics Limited |
Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
|
|
KR101334511B1
(ko)
|
2004-12-30 |
2013-11-29 |
아스텍스 테라퓨틱스 리미티드 |
Ｃｄｋ, ｇｓｋ 및 오로라 키나아제의 활성을 조절하는피라졸 화합물
|
|
EP1836199A1
(en)
|
2004-12-30 |
2007-09-26 |
Astex Therapeutics Limited |
Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
|
|
WO2006070202A1
(en)
|
2004-12-30 |
2006-07-06 |
Astex Therapeutics Limited |
Pyrazole derivatives having kinase modulating activity
|
|
US7485661B2
(en)
|
2005-01-18 |
2009-02-03 |
Pfizer Italia S.R.L. |
Heterobicyclic pyrazole derivatives as kinase inhibitors
|
|
WO2007041358A2
(en)
|
2005-09-30 |
2007-04-12 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
|
WO2007056163A2
(en)
|
2005-11-03 |
2007-05-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
TW200808311A
(en)
|
2006-03-30 |
2008-02-16 |
Nerviano Medical Sciences Srl |
Use of a kinase inhibitor for the treatment of particular resistant tumors
|
|
WO2007132221A1
(en)
|
2006-05-12 |
2007-11-22 |
Cyclacel Limited |
Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
|
|
GB0609530D0
(en)
|
2006-05-12 |
2006-06-21 |
Cyclacel Ltd |
Combination
|
|
WO2007132220A1
(en)
|
2006-05-12 |
2007-11-22 |
Cyclacel Limited |
Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
|
|
WO2008021038A2
(en)
|
2006-08-09 |
2008-02-21 |
Millennium Pharmaceuticals, Inc. |
Pyridobenzazepine compounds and methods for inhibiting mitotic progression
|
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
ES2468391T3
(es)
*
|
2008-12-22 |
2014-06-16 |
Millennium Pharmaceuticals, Inc. |
Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20
|
|
EP2376110B1
(en)
|
2009-01-09 |
2019-03-13 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
|
JO3434B1
(ar)
|
2009-07-31 |
2019-10-20 |
Millennium Pharm Inc |
مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
|
|
JP2013520424A
(ja)
|
2010-02-19 |
2013-06-06 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|